oncology

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the

23 November 2025

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc (LON:GSK, NYSE:GSK) finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop. Key takeaways

20 November 2025

Analyst Ratings · Oncology · Pharma News · Share Prices · Stock Market

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on

17 November 2025

Biotech Industry · Mergers & Acquisitions · NASDAQ:CDTX · NYSE:JNJ · NYSE:MRK · NYSE:PFE · Oncology · Patent News · Pharmaceuticals

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs

11 November 2025

Business News · Mergers & Acquisitions · NYSE:MRK · NYSE:NVO · NYSE:PFE · Oncology · Pharmaceuticals · Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)

10 November 2025

Biotechnology · Clinical Trials · NASDAQ:COGT · Oncology · Pharmaceutical News · Stock Market